Pharmsynthesis

Pharmsynthesis is a Russian pharmaceutical company specializing in the development and production of drugs for treatment of socially significant diseases such as tuberculosis, HIV infection, oncology, diabetes and hepatitis. The company has been on the pharmaceutical market since 1997; its plants are located in Irkutsk, Ussuriysk, Tyumen, Bratsk and St. Petersburg.
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

Pharmsynthesis balance sheet

Report period2019 2020 2021 2022 2023 Q1 24
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Pharmsynthesis cash flows

Report period2019 2020 2021 2022 2023 Q1 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
EPS

Pharmsynthesis multipliers

Report period2019 2020 2021 2022 2023 Q1 24 TTM
P/E
E/P
P/B
P/S
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Pharmsynthesis profitability

Report period2019 2020 2021 2022 2023 Q1 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Pharmsynthesis assets
Pharmsynthesis cash flows
Pharmsynthesis dividends
0%

Pharmsynthesis shares

TickerNameTypeNominal valueISINPrice
LIFE:RMPharmsynthesisCommon shareRUB 5RU000A0JR514RUB 4.525

Pharmsynthesis expected events

DateTypeNoteSource
19.06.2024 13:00
Other Issuer Events
AGM on additional share issue  disclosure.skrin.ru
28.06.2024 12:00
Meeting of shareholders
Shareholders will decide on dividends for 2023 year  disclosure.skrin.ru
Share capital structure of Pharmsynthesis
Pharmsynthesis news
07.05.2024
Pharmsintez's RAS loss for 3 months of 2024 amounted to ₽241.57 million, down 8.7% from ₽264.54 million in the previous year. Revenue declined 7.9% to ₽284.64 million from ₽309.09 million a year earlier.
11.04.2024
Pharmsintez's RAS loss for 2023 amounted to ₽241.57 million, down 8.7% from ₽264.54 million in the previous year. Revenue declined 8% to ₽284.4 million from ₽309.09 million a year earlier.
16.02.2024
Pharmsintez sold the Estonian plant Kevelt. The buyer was Dmitry Genkin, Chairman of the Board of Directors of the company. Transactions amounted to €224.8 thousand. At the same time, the parties entered into an option, according to which Pharmsintez has the right to buy back the shares within ten years. Companies also offset the counterclaims on the debt of...
Source: {source} pictogram dp.ru
20.11.2023
Board of Directors of Pharmsintez convened a meeting of shareholders to resolve the issue of increasing the authorized capital by placing additional shares by public subscription. Meeting will be held on December 21.
General information
Company namePharmsynthesis
Tags#pharmacy, #innovations of the russia
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressRossiyskaya Federaciya, Leningradskaya oblast, Vsevolozhskiy rayon
Mailing address188663 Rossiyskaya Federaciya, Leningradskaya oblast, Vsevolozhskiy rayon, gorodskoy poselok Kuzmolovskiy, stanciya Kapitolovo, 134 str. 1
CEOPrilezhaev Efim Aleksandrovich
Phone329-80-80
Websitepharmsynthez.com
Information disclosuree-disclosure.ru